<DOC>
	<DOCNO>NCT02936089</DOCNO>
	<brief_summary>Acute myeloid leukemia ( 8 ; 21 ) /AML1-ETO-positive ( AE AML ) heterogeneous disease entail different prognosis . There significant difference therapeutic effect different subgroup AE AML . Therefore , risk stratification-directed therapy necessary AE AML .</brief_summary>
	<brief_title>Risk Stratification-directed Therapy AML With ( 8 ; 21 ) /AML1-ETO+</brief_title>
	<detailed_description>Acute myeloid leukemia ( 8 ; 21 ) /AML1-ETO-positive ( AE AML ) heterogeneous disease entail different prognoses.There significant difference therapeutic effect different subgroup AE AML . For example , patient c-kit mutation high relapse rate lower overall survival , compare without c-kit mutation . Therefore , risk stratification-directed therapy necessary AE AML . The purpose study establish risk stratification-directed therapy AE AML .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>AE AML age 1560 No abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) Expected survival time 2 month Any abnormality vital sign ( e.g. , heart rate , respiratory rate , blood pressure ) Patients condition suitable trial ( investigator ' decision )</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>